How to buy Biofrontera stock (BFRI)

Biofrontera is a drug manufacturers - specialty & generic business based in the US. Biofrontera shares (BFRI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.11 – an increase of 13.44% over the previous week. Biofrontera employs 83 staff and has a trailing 12-month revenue of around $35.2 million.

Our top picks for where to buy Biofrontera stock

Buy Biofrontera stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biofrontera stock price (NASDAQ: BFRI)

Use our graph to track the performance of BFRI stocks over time.

Biofrontera shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.11
52-week range	$0.61 - $3.90
50-day moving average more info button	$0.94
200-day moving average more info button	$1.17
Wall St. target price	$11.50
PE ratio more info button	0.8707
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.16

Is it a good time to buy Biofrontera stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biofrontera price performance over time

Historical closes compared with the close of $1.07 from 2024-12-26

1 week (2024-12-20)	9.35%
1 month (2024-11-27)	8.08%
3 months (2024-09-27)	-16.41%
6 months (2024-06-27)	18.89%

1 year (2023-12-27)	-62.06%
2 years (2022-12-27)	-93.71%
3 years (2021-12-27)	229.8
5 years (2019-12-24)	N/A

Is Biofrontera stock undervalued or overvalued?

Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biofrontera's P/E ratio

Biofrontera's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Biofrontera shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Biofrontera's P/E ratio is best considered in relation to those of others within the drug manufacturers - specialty & generic industry or those of similar companies.

• Arcutis Biotherapeutics Inc (ARQT.US): 0.00
• Cutera (CUTR.US): 0.00
• Anika Therapeutics (ANIK.US): 0.00

Biofrontera financials

Revenue TTM	$35.2 million
Gross profit TTM	$13.5 million
Return on assets TTM	-40.24%
Return on equity TTM	-149.41%
Profit margin	-38.34%
Book value	$3.16
Market Capitalization more info button	$7.8 million

TTM: trailing 12 months

Biofrontera share dividends

We're not expecting Biofrontera to pay a dividend over the next 12 months.

You may also wish to consider:

Have Biofrontera's shares ever split?

Biofrontera's shares were split on a 1:20 basis on 4 July 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biofrontera shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Biofrontera shares which in turn could have impacted Biofrontera's share price.

Biofrontera share price volatility

Over the last 12 months, Biofrontera's shares have ranged in value from as little as $0.61 up to $3.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 0.509. This would suggest that Biofrontera's shares are less volatile than average (for this exchange).

To put Biofrontera's beta into context you can compare it against those of similar companies.

• Arcutis Biotherapeutics Inc (ARQT.US): 1.185
• Cutera (CUTR.US): 1.353
• Anika Therapeutics (ANIK.US): 0.857

Biofrontera overview

Biofrontera Inc. , a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. .

Frequently asked questions

null
What percentage of Biofrontera is owned by insiders or institutions?
Currently 32.064% of Biofrontera shares are held by insiders and 20.68% by institutions. How many people work for Biofrontera?
Latest data suggests 83 work at Biofrontera. When does the fiscal year end for Biofrontera?
Biofrontera's fiscal year ends in December. Where is Biofrontera based?
Biofrontera's address is: 120 Presidential Way, Woburn, MA, United States, 01801 What is Biofrontera's ISIN number?
Biofrontera's international securities identification number is: US09077D1000